OPK Opko Health Inc.

3.29
-0.12  -4%
Previous Close 3.41
Open 3.37
Price To Book 1.08
Market Cap 1929031665
Shares 586,331,813
Volume 2,954,477
Short Ratio
Av. Daily Volume 4,228,703

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data due 1Q 2019.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b enrollment to be completed YE 2018.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 trial initiation announced September 4, 2018. Data from first cohort due 2019.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 completion of enrollment announced August 3, 2018.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

SEC Filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181195930
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181195904
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173185
  4. 8-K - Current report 181173156
  5. 8-K - Current report 181071747
  6. 8-K - Current report 181064126
  7. 8-K - Current report 181061402
  8. 8-K - Current report 181001376
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998340
  10. 8-K - Current report 18998109